- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04510805
Effectiveness of NextDose for Warfarin Dose Individualization
Single-blind, Randomized Comparison of Warfarin Management Guided by NextDose Versus Management Based on Clinician Experience.
Objectives:
To understand whether the implementation of warfarin dose management using NextDose (nextdose.org) at The First Affiliated Hospital of Soochow University (Suzhou, China) improves the quality of anticoagulation therapy.
Endpoint Primary
1. Percentage of time within the acceptable INR range estimated using linear interpolation during the 28 days after initiation of warfarin.
Secondary 2.1 Percentage of Time Measures 2.2 Time to Stable Dose 2.3 Safety Outcomes 2.4 Acceptability of NextDose Recommendations Exploratory 3.1 Percentage of Time Measures 3.2 Time to Stable Dose 3.3 Safety Outcomes 3.4 Acceptability of NextDose Recommendations 3.5 Model Evaluation 3.6 INR Variability
Population:
240 participants of any sex between the age of 18 and 80 years. Patients requiring treatment with warfarin following cardiac surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
To understand whether the implementation of warfarin dose management using NextDose (nextdose.org) at The First Affiliated Hospital of Soochow University (Suzhou, China) improves the quality of anticoagulation therapy.
Endpoint Primary
Percentage of time within the acceptable INR range estimated using linear interpolation during the 28 days after initiation of warfarin.
Secondary 2.1 Percentage of Time Measures
- Percentage of time within the acceptable INR Range estimated using linear interpolation during the 90 days after initiation of warfarin.
- Percentage of time spent above and below the acceptable INR range at day 28, and 90 after initiation of warfarin estimated by linear interpolation.
2.2 Time to Stable Dose a. Number of days to achievement of stable dose (defined as 3 consecutive INR measurements within acceptable range for the same mean daily dose).
2.3 Safety Outcomes a. Number of participants who experience at least one of the following safety events: major bleeding within 30 days, INR of 4 or greater within 30 days, death within 30 days, and symptomatic or asymptomatic VTE confirmed by objective testing within 60 days of surgery.
2.4 Acceptability of NextDose Recommendations
- Percentage of prescribed doses within 0.625 mg of the NextDose proposed dose.
- Mean difference between the prescribed dose and the NextDose proposed dose. Exploratory 3.1 Percentage of Time Measures
a. The percentage of time spent within, above and below the acceptable INR range estimated by numerical integration with the Bayesian parameter estimates of the PKPD model at day 28 and at day 90 after initiation of warfarin.
3.2 Time to Stable Dose a) Days to first INR measurement within the acceptable range. b) Days to second consecutive INR measurement within the acceptable range. c) Number of dose adjustments to achievement of stable dose (3 consecutive INR measurements within acceptable range for the same mean daily dose).
d) Total number of dose adjustments at day 90. e) Total number of INR measurements at day 90. 3.3 Safety Outcomes
a) Incidence of minor and major bleeding events. b) Incidence of thromboembolic events. c) 30 day all-cause mortality. d) 90 day all-cause mortality. e) 90 day cardiovascular mortality. f) Number of warfarin doses withheld due to high INR (as determined by the treating clinician).
3.4 Acceptability of NextDose Recommendations a) Percentage of prescribed doses within 20% of the NextDose proposed dose. 3.5 Model Evaluation
a) Predictive performance of the model for patients with steady-state warfarin doses below 2 or above 7 mg/day.
3.6 INR Variability
a) INR variability as described by Lind et al. (the standard deviation of transformed INR values).
Population:
240 participants of any sex between the age of 18 and 80 years. Patients requiring treatment with warfarin following cardiac surgery.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ling Xue, MS
- Phone Number: +8651267972699 +8651267972699
- Email: xueling726@126.com
Study Contact Backup
- Name: Qiong Qin, MS
- Phone Number: +8651267973022 +8651267973022
- Email: q-q2456@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Scheduled to undergo cardiac surgery with planned warfarin anticoagulation for at least three months.
- Age ≥ 18 and < 80 years.
- Written informed consent has been obtained.
Exclusion Criteria:
- Allergy to warfarin tablet or excipients.
- Enrollment or planned enrollment in other research that would conflict with full participation in the study or confound the observation or interpretation of the study findings.
Patients who in the opinion of the recruiting clinician are:
- unwilling or unable to comply with the protocol requirements and/or,
- considered unreliable concerning the requirements for follow-up during the study and/or, compliance with drug administration.
- Patient with life expectancy less than the expected duration of the trial due to concomitant disease.
Contraindication to warfarin therapy. The following are examples but not an exhaustive list:
- Pregnancy.
- Cerebral infarction or cerebral haemorrhage (from patients' medical record) within the 3 months prior to heart valve replacement
- Severe heart failure (New York Heart Function Class IV)
- Severe renal failure (CLcr (Cockcroft-Gault) ≤20mL / min)
- Severe liver failure (Child-Pugh≥10)
- Abnormal liver function (elevated transaminase more than three times the upper limit of the local hospital clinical laboratory).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles. Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose. |
NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles. Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose. |
No Intervention: Control Arm
Usual standard of care.
Clinical experience of the treating physician taking into account the covariates, dosing and INR history of each patient, to determine the initial, and subsequent maintenance doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Time Within Range
Time Frame: 28 days after initiation of warfarin
|
The percentage of time spent within the acceptable INR range (± 0.5 of target INR) as estimated using linear interpolation during the 28 days after initiation of warfarin.
|
28 days after initiation of warfarin
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Time Measure
Time Frame: day 90 after initiation of warfarin
|
The percentage of time spent within the acceptable INR range at day 90 after initiation of warfarin estimated by linear interpolation.
|
day 90 after initiation of warfarin
|
Percentage of Time Measure
Time Frame: day 28, and 90 after initiation of warfarin
|
The percentage of time spent above and below the acceptable INR range at day 28, and 90 after initiation of warfarin estimated by linear interpolation.
|
day 28, and 90 after initiation of warfarin
|
Time to Stable Dose
Time Frame: 90 days after initiation of warfarin
|
Number of days to achievement of stable dose (defined as 3 consecutive INR measurements within acceptable range for the same mean daily dose.
|
90 days after initiation of warfarin
|
Number of participants who experience at least one of the following safety events:
Time Frame: 60 days of surgery.
|
major bleeding within 30 days, INR of 4 or greater within 30 days, death within 30 days, and symptomatic or asymptomatic VTE confirmed by objective testing within 60 days of surgery.
|
60 days of surgery.
|
Percentage of prescribed doses within 0.625 mg of the NextDose proposed dose.
Time Frame: 90 days after initiation of warfarin
|
Acceptability of NextDose Recommendations
|
90 days after initiation of warfarin
|
Mean difference between the prescribed dose and the NextDose proposed dose.
Time Frame: 90 days after initiation of warfarin
|
Acceptability of NextDose Recommendations
|
90 days after initiation of warfarin
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Li Y Miao, PhD, The First Affiliated Hospital of Soochow University
- Principal Investigator: Zhen Y Shen, PhD, The First Affiliated Hospital of Soochow University
- Study Director: Nick Holford, MBChB, University of Auckland, New Zealand
- Study Director: Ling Xue, MS, The First Affiliated Hospital of Soochow University
- Study Director: Guangda Ma, MHSc, University of Auckland, New Zealand
- Study Director: Ying L Ding, MS, The First Affiliated Hospital of Soochow University
- Study Director: Qiong Qin, MS, The First Affiliated Hospital of Soochow University
- Study Director: Jacqui Hannam, PhD, University of Auckland, New Zealand
Publications and helpful links
General Publications
- Sheiner LB. Computer-aided long-term anticoagulation therapy. Comput Biomed Res. 1969 Dec;2(6):507-18. doi: 10.1016/0010-4809(69)90030-5. No abstract available.
- Boyle DA, Ludden TM, Carter BL, Becker AJ, Taylor JW. Evaluation of a Bayesian regression program for predicting warfarin response. Ther Drug Monit. 1989;11(3):276-84. doi: 10.1097/00007691-198905000-00010.
- Xue L, Holford N, Ding XL, Shen ZY, Huang CR, Zhang H, Zhang JJ, Guo ZN, Xie C, Zhou L, Chen ZY, Liu LS, Miao LY. Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients. Br J Clin Pharmacol. 2017 Apr;83(4):823-835. doi: 10.1111/bcp.13157. Epub 2016 Nov 25. Erratum In: Br J Clin Pharmacol. 2017 Jul;83(7):1602.
- Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. doi: 10.1001/jama.287.13.1690.
- Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x.
- Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011 Jan 18;57(3):253-69. doi: 10.1016/j.jacc.2010.12.005. Epub 2011 Jan 7.
Helpful Links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombosis Embolism
-
Azienda Sanitaria ULSS 13 Dolo, MiranoUnknownEmbolism and Thrombosis of the Radial ArteryItaly
-
British Thoracic SocietyCompletedDeep Vein Thrombosis | Pulmonary Embolism | Deep Vein Thrombosis With Pulmonary EmbolismUnited Kingdom
-
Rennes University HospitalSFMV (French Society of Vascular Medicine)UnknownVenous Thrombosis or Pulmonary EmbolismFrance
-
Diagnostica Stago R&DHopital Lariboisière; Hôpital Louis MourierCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)France
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR)TerminatedDeep Venous Thrombosis | Suspected Pulmonary EmbolismCanada
-
Mayo ClinicRecruitingAcute Pulmonary Embolism | Acute Deep Vein ThrombosisUnited States
-
Hellenic Society of Medical OncologyUnknownDeep Vein Thrombosis | Pulmonary Embolism | Vena Cava Thrombosis | Iliac; ThrombosisGreece
-
BayerJanssen Research & Development, LLCCompletedDeep Vein Thrombosis (DVT) | Pulmonary Embolism (PE)Turkey, Russian Federation, Korea, Republic of, Mexico, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Egypt, Kazakhstan, Algeria, Lebanon, Saudi Arabia, Ukraine, Jordan, Kenya, Kuwait, Morocco, Qatar, United Arab Emirates
-
Heart and Vascular Outcomes Research InstituteUnknownVenous Thromboembolism, | Pulmonary Embolism, | Deep Vein Thrombosis,
-
Wei HuangCompletedVenous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Anticoagulants